Spacetalk Ltd(SPA.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

SPA.AU Spacetalk Ltd

Not Yet Opened 05-17 16:12:00 AEST

0.02

+0.00

0.00%

High0.02	Low0.02	Vol172.55K
Open0.02	D1 Closing0.02	Amplitude0.00%
Mkt Cap8.95M	Tradable Cap6.28M	Total Shares471.02M
T/O3.28K	T/O Rate0.05%	Tradable Shares330.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPA.AU","market":"AU","secType":"STK","nameCN":"Spacetalk Ltd","latestPrice":0.019,"timestamp":1715926320000,"preClose":0.019,"halted":0,"volume":172552,"delay":0,"nameEN":"Spacetalk Ltd","floatShares":330674221,"shares":471021409,"eps":-0.026573,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-17 16:12:00 AEST","open":0.019,"high":0.019,"low":0.019,"amount":3278,"amplitude":0,"askPrice":0.02,"askSize":591812,"bidPrice":0.019,"bidSize":111803,"shortable":3,"etf":0,"ttmEps":-0.026573,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.019,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":0.6648116624329902,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/SPA.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2435524523","title":"Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435524523","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435524523?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:30","pubTimestamp":1715718600,"startTime":"0","endTime":"0","summary":"Company received written agreement from the U.S. FDA under a Special Protocol Assessment  on the design for a Phase 3b trial of NurOwn. Conference call planned for later this quarter to provide update on NurOwn program. NEW YORK, May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update.--  In April 2024, BrainStorm received written agreement from the U.S. Food. and Drug Administration , under a Special Protocol Assessment ,sclerosis . The SPA agreement validates the clinical trial protocol. and statistical analysis of the planned Phase 3b trial of NurOwn,demonstrating their adequacy for addressing objectives that support a. initiating the Phase 3b study in 2024, after reviewing the protocol with. investigators, securing study site Institutional Review Board approvals,in Muscle and Nerve i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435332685","title":"Press Release: Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2435332685","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435332685?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:02","pubTimestamp":1715598120,"startTime":"0","endTime":"0","summary":"Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, \"Our primary corporate objective is the advancement of our lead asset, EryDex, for the treatment of patients with ataxia-telangiectasia. We remain on track to begin enrollment of our pivotal Phase 3 study in the second quarter of 2024 and will diligently pursue enrollment at U.S. and European study sites to provide an opportunity for patients living with this rare, devastating disease to participate in research to identify a beneficial therapeutic solution.\"We are pleased to report the selection of Duchenne muscular dystrophy  as Quince's second development program for EryDex. We consider DMD a promising indication for EryDex as corticosteroids are the standard of care for this rare disease, but its utility is limited by significant chronic toxicity due to adrenal suppression. We believe EryDex has the potential to provide the therapeutic benefit of corticosteroids without this chronic toxicity. Physicia","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433750740","title":"ASX lithium stock suspended for 8 months gearing up to resume trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2433750740","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2433750740?lang=en_us&edition=fundamental","pubTime":"2024-05-08 08:37","pubTimestamp":1715128677,"startTime":"0","endTime":"0","summary":"It has been a long time since Leo Lithium Ltd  shares have been seen on the ASX boards.The Africa-based ASX lithium stock has been out of action since the middle of September.This has been caused by issues arising from the introduction of a new Mining Code in Mali which impacted its Goulamina Lithium Project.This includes Leo Lithium entering into a further binding share sale and purchase agreement  to sell its remaining 40% interest in the Goulamina Lithium Project to Ganfeng Lithium for US$342.7 million.The ASX lithium stock advised that the US$342.7 million cash consideration that is payable by Ganfeng Lithium is structured as follows:. US$10.5 million non-refundable deposit to be paid within 10 days of executing the sale and purchase agreement.US$161.0 million payable on completion of the transaction following satisfaction of conditions precedent.US$171.2 million payable on 30 June 2025 or an earlier date.Management notes that US$342.7 million is equivalent to A$0.43 per Leo Lithiu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/08/asx-lithium-stock-suspended-for-8-months-gearing-up-to-resume-trading/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429111214","title":"Spero Therapeutics Delivers On Game Plan To Create Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2429111214","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2429111214?lang=en_us&edition=fundamental","pubTime":"2024-04-23 23:37","pubTimestamp":1713886637,"startTime":"0","endTime":"0","summary":"Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential.Spero has excellen","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413265641/image_1413265641.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413265641/image_1413265641.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685311-spero-therapeutics-delivers-on-game-plan-to-create-shareholder-value","is_publish_highlight":false,"gpt_icon":0},{"id":"2429405549","title":"Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2429405549","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429405549?lang=en_us&edition=fundamental","pubTime":"2024-04-22 20:00","pubTimestamp":1713787200,"startTime":"0","endTime":"0","summary":"FARMINGTON HILLS, Mich., April 22, 2024  -- Ocuphire Pharma, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology  Annual Meeting to be held May 5-9, 2024 in Seattle, Washington.Key details about Dr. Su's presentation at the ARVO 2024 Annual Meeting are below:. Oral APX3330, a Ref-1 Inhibitor, Slows Progression of. In addition, Ocuphire has a partnership with Viatris to develop and commercialize Phentolamine Ophthalmic Solution 0.75% , a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. PS was approved by the FDA for the treatment for pharmacologically-induced mydriasis under the brand name RYZUMVI in September 2023. PS is also in Phase 3 clinical development for the treatment of presbyopia and for the treatment","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428571012","title":"BUZZ-Australia's COSOL jumps on acquiring asset management consultancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2428571012","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428571012?lang=en_us&edition=fundamental","pubTime":"2024-04-19 10:00","pubTimestamp":1713492032,"startTime":"0","endTime":"0","summary":"** Shares of asset management company COSOL    rise as much as 1.5% to A$1.00   ** COS set for best week since March 29   ** Co says it entered into a binding Share Purchase Agreement to acquire asset management consultancy Core Asset Co for A$6.1 mln    ** Stock down 0.5% so far this year, as of last close  ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428381339","title":"Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn","url":"https://stock-news.laohu8.com/highlight/detail?id=2428381339","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428381339?lang=en_us&edition=fundamental","pubTime":"2024-04-17 06:31","pubTimestamp":1713306660,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn. Dr. Dagher has served as our Chief Development Officer since July 2023. In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn. The Company recently announced that it has reached agreement with the U.S. Food & Drug Administration  for a Special Protocol Assessment  for this trial.Dr. Dagher has over 20 years' of experience in clinical research and development, with a proven track record of leading successful clinical trials and fostering innovation in drug development. Prior to joining Brainstorm he was Chief Medical Officer at Enveric Biosciences where he was responsible for defining the portfolio strategy and advancement of development plans toward regulatory approvals. He began his career in biopharmaceuticals as a medical scientist at GSK, and has se","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2426864167","title":"BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2426864167","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426864167?lang=en_us&edition=fundamental","pubTime":"2024-04-09 18:58","pubTimestamp":1712660304,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics  traded higher in the premarket Tuesday after announcing that the U.S. FDA has endorsed the design of a late-stage trial for its cell therapy candidate NurOwn for amyotrophic lateral sclerosis, a neurological disease. The company said the regulator sent a written confirmation of a so-called Special Protocol Assessment , validating the critical trial components such as protocol and statistical analysis of its planned Phase 3b study.  The two-part trial is expected to start in 2024 across multiple study sites for patients with ALS who are in the earlier stages of the disease. \"We believe that having this SPA in place will help de-risk certain regulatory aspects of the NurOwn clinical program,\" BrainStorm  CEO Chaim Lebovits remarked.    More on BrainStorm Cell Therapeutics  BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088132-brainstorm-stock-gains-fda-oks-als-trial","is_publish_highlight":false,"gpt_icon":0},{"id":"2424792309","title":"Press Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2424792309","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2424792309?lang=en_us&edition=fundamental","pubTime":"2024-04-01 19:00","pubTimestamp":1711969200,"startTime":"0","endTime":"0","summary":"Quince Therapeutics, Inc. , a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.\"With the acquisition of EryDel S.p.A. in October last year, we have successfully shifted our strategic focus to become a Phase 3 biotechnology company dedicated to securing regulatory approval for our lead product, EryDex, for the treatment of patients with Ataxia-Telangiectasia (A-T),\" said Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer. \"With $75.1 million cash on hand, we expect to have sufficient funding to complete our Phase 3 clinical trial, in addition to supporting the expansion of EryDex into other indications and our Autologous Intracellular Drug Encapsulation  technology platform into new products. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2423173176","title":"There's No Escaping Spacetalk Limited's (ASX:SPA) Muted Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2423173176","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2423173176?lang=en_us&edition=fundamental","pubTime":"2024-03-29 04:26","pubTimestamp":1711657573,"startTime":"0","endTime":"0","summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 0.6x Spacetalk Limited ( ASX:SPA ) is definitely a stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-spa/spacetalk-shares/news/theres-no-escaping-spacetalk-limiteds-asxspa-muted-revenues","is_publish_highlight":false,"gpt_icon":0},{"id":"2421310935","title":"Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=2421310935","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421310935?lang=en_us&edition=fundamental","pubTime":"2024-03-24 12:46","pubTimestamp":1711255584,"startTime":"0","endTime":"0","summary":"Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease.Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiere","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397661322/image_1397661322.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397661322/image_1397661322.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4680108-aldeyra-derisked-biotech-eyeing-path-to-approval-and-finalizing-deal-with-abbvie","is_publish_highlight":false,"gpt_icon":0},{"id":"2420418669","title":"Metarock Group announces $65M sale of PYBAR business to Thiess","url":"https://stock-news.laohu8.com/highlight/detail?id=2420418669","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2420418669?lang=en_us&edition=fundamental","pubTime":"2024-03-18 12:33","pubTimestamp":1710736380,"startTime":"0","endTime":"0","summary":"Metarock Group confirms the execution of a binding Share Sale and Purchase Agreement  to sell its entire interest in the PYBAR business  to Thiess. Transaction amounts to A$65 million based on enterprise value. Metarock Group  has confirmed the execution of a binding Share Sale and Purchase Agreement  to sell its entire interest in the PYBAR business  to Thiess Pty Ltd, a wholly owned subsidiary of Thiess Group Holdings .PYBAR is ultimately an underground mining contractor; Metarock shares jumped 10% on the news pushing the stock to 21c in late afternoon trades.The total consideration for the deal amounts to A$65 million based on enterprise value.Metarock expects to receive $36.3 million in net cash proceeds after accounting for PYBAR’s outstanding debt and estimated transaction costs.“The purchase consideration represents compelling value for the PYBAR business, which will continue to grow as part of Thiess’ global mining services platform,” Metarock chief Jon Romcke said.Under the te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/metarock-group-announces-65m-sale-of-pybar-business-to-thiess-2024-03-18/","is_publish_highlight":false,"gpt_icon":0},{"id":"2419553962","title":"BRIEF-Spacetalk Ltd Says Tonderai Maenzanise To Step Down As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2419553962","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419553962?lang=en_us&edition=fundamental","pubTime":"2024-03-15 09:37","pubTimestamp":1710466648,"startTime":"0","endTime":"0","summary":"March 15 (Reuters) - Spacetalk Ltd   :   * TONDERAI MAENZANISE STEPS DOWN AS CFO   * APPOINTMENT OF GERHARD BEUKES AS INTERIM CFOFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418358443","title":"Saudi Aramco Eyes Q3 Start-up for Jazan 800 kt/year PX Unit -- OPIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2418358443","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2418358443?lang=en_us&edition=fundamental","pubTime":"2024-03-11 19:28","pubTimestamp":1710156480,"startTime":"0","endTime":"0","summary":"Saudi Arabian Oil Co.  is eyeing a start-up of its Jazan paraxylene  unit in the third quarter of 2024, according to a market source on March 11.The company is making progress on its 800,000 metric tons  per year PX plant, but there remains no official start-up timeline, according to the source.Market participants have been keeping a close watch on Jazan's progress, it being one of the few new PX plants yet to commence production.Jazan's PX unit was last expected to debut in June 2023, along with those from Sinopec, PetroChina, Cnooc, and Zhejiang Petrochemical in the same year, OPIS reported.\"Jazan's PX delay has to do with better margins in gasoline,\" said Duncan Clark, Vice President, and Global Aromatics & Fibers Team Lead at Chemical Market Analytics  by OPIS.\"Aramco's overall PX operating rate is less than 60% at present,\" added Ashish Pujari, Vice President of Aromatics and Fibers at CMA.Aramco's Jazan PX unit has been delayed by over seven years, data from OPIS showed. The plan","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2415551918","title":"BUZZ-Australia's Metro Mining hits over 21-mnth high on FY24 forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2415551918","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2415551918?lang=en_us&edition=fundamental","pubTime":"2024-02-29 11:06","pubTimestamp":1709176017,"startTime":"0","endTime":"0","summary":"** Shares of Metro Mining    rise 6.9% to A$0.030, their highest since May 2022; last up 3.5%   ** Bauxite miner sets forecast for production and shipment at 6.3 mln to 6.8 mln wet metric tonnes for 2024   ** Says underlying EBITDA improved to A$18.5 mln  compared to loss of A$24.8 mln   ** About 12 mln shares change hands, compared with the 30-day average volume of 6.6 mln shares   ** Stock up 42.9% so far this year  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415653447","title":"BRIEF-Spacetalk Says HY Loss Attributable A$4.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2415653447","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2415653447?lang=en_us&edition=fundamental","pubTime":"2024-02-29 09:22","pubTimestamp":1709169728,"startTime":"0","endTime":"0","summary":"Feb 29 (Reuters) - Spacetalk Ltd   :   * LOSS FOR HALF-YEAR ATTRIBUTABLE A$4.0 MILLION VERSUS LOSS A$9.2 MILLION   * HY REVENUE FROM ORDINARY ACTIVITIES A$9.4 MILLION VERSUS A$9.3 MILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415553688","title":"BRIEF-Spacetalk Ltd Says HY Annual Recurring Revenue (Arr) Increased 28% On The Prior Corresponding Period (“Pcp”) To A$9.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2415553688","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2415553688?lang=en_us&edition=fundamental","pubTime":"2024-02-29 08:27","pubTimestamp":1709166445,"startTime":"0","endTime":"0","summary":"Feb 29  - Spacetalk Ltd   :   * HY ANNUAL RECURRING REVENUE  INCREASED 28% ON THE PRIOR CORRESPONDING PERIOD  TO A$9.5M   * IN HY ACTIVE SUBSCRIBER GROWTH FOR SPACETALK MOBILE  GREW 272% ON PCP TO OVER 26,000 ACTIVE  SUBSCRIBERSSource text for Eikon:    Further company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414864440","title":"Press Release: Woodside Releases Full-Year 2023 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2414864440","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2414864440?lang=en_us&edition=fundamental","pubTime":"2024-02-27 07:43","pubTimestamp":1708990980,"startTime":"0","endTime":"0","summary":"Woodside has achieved record production of 187.2 MMboe  and excellent operated LNG reliability of 98%. We recorded full-year net profit after tax  of $1,660 million, and underlying NPAT of $3,320 million when adjusted for exceptional items, and operating cash flow was $6,145 million.The Directors have determined a final dividend of US 60 cents per share , bringing the full-year dividend to US 140 cps. The dividend is fully franked. The value of the total full-year dividend is $2,658 million.Woodside CEO Meg O'Neill said she was tremendously proud that at a time of inflationary pressures, Woodside continued to return strong dividends to shareholders while delivering on our strategy to thrive through the energy transition.\"Our debt-free merger with BHP Petroleum added cash generating assets and strengthened Woodside's balance sheet, giving us capacity for future capital investments as well as ongoing returns. Gearing at year-end was 12.1% and our total available liquidity was $7.8 billio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2409267304","title":"BWP Trust and Newmark Property REIT endorse $250m merger to enhance real estate portfolios","url":"https://stock-news.laohu8.com/highlight/detail?id=2409267304","media":"Small Caps","top":-1,"share":"https://ttm.financial/m/news/2409267304?lang=en_us&edition=fundamental","pubTime":"2024-02-07 11:42","pubTimestamp":1707277321,"startTime":"0","endTime":"0","summary":"The boards of real estate financing specialists BWP Trust  and Newmark Property REIT  continue to back a proposed $250 million merger announced in late January.In releasing its bidder’s statement and half-year results today, BWP management said the bid implementation deed takeover offer for Newmark makes strong sense for both companies.BWP, a real estate investment trust  investing in and managing commercial properties throughout Australia, says the merger proposal provides an opportunity to combine BWP’s and NPR’s complementary portfolios of quality assets and similar tenant profiles.Managing director Mark Scatena said the proposal reflects BWP’s focus on profitably growing the portfolio through assets with strong location attributes and tenant covenants.Among the benefits to BWP unitholders, Mr Scatena said the larger portfolio will increase the scale and relevance of the company, supporting its ongoing strategy to create long-term value through the addition of nine quality large for","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/02/BWP-NPR-REIT-merger-ASX-property.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/02/BWP-NPR-REIT-merger-ASX-property.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/bwp-trust-newmark-property-reit-merger-enhance-real-estate-portfolios/","is_publish_highlight":false,"gpt_icon":0},{"id":"2409638233","title":"Otway Basin seismic petroleum exploration proposal in whale nursery 'a slap in the face'","url":"https://stock-news.laohu8.com/highlight/detail?id=2409638233","media":"ABC News","top":-1,"share":"https://ttm.financial/m/news/2409638233?lang=en_us&edition=fundamental","pubTime":"2024-02-07 03:53","pubTimestamp":1707249221,"startTime":"0","endTime":"0","summary":"Geoscience technology services company CGG formally submitted its permit application and environmental plan in late January amid a month-long campaign of community protests.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"abcau_stock","url":"https://www.abc.net.au/news/2024-02-07/oil-and-gas-survey-permit-moves-to-next-stage/103404020","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.abc.net.au/news/2024-02-07/oil-and-gas-survey-permit-moves-to-next-stage/103404020","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mgmwireless.com","stockEarnings":[{"period":"1week","weight":-0.1364},{"period":"1month","weight":-0.24},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.4412},{"period":"ytd","weight":-0.2692}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.070157},{"month":2,"riseRate":0.25,"avgChangeRate":0.028846},{"month":3,"riseRate":0.5,"avgChangeRate":-0.026618},{"month":4,"riseRate":0,"avgChangeRate":-0.207507},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.035986},{"month":6,"riseRate":0.666667,"avgChangeRate":0.065392},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035088},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.054579},{"month":9,"riseRate":0,"avgChangeRate":-0.102484},{"month":10,"riseRate":0,"avgChangeRate":-0.166005},{"month":11,"riseRate":0.25,"avgChangeRate":0.013321},{"month":12,"riseRate":0.5,"avgChangeRate":0.063882}],"exchange":"ASX","name":"Spacetalk Ltd","nameEN":"Spacetalk Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spacetalk Ltd(SPA.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spacetalk Ltd(SPA.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spacetalk Ltd,SPA.AU,Spacetalk Ltd股票,Spacetalk Ltd股票老虎,Spacetalk Ltd股票老虎国际,Spacetalk Ltd行情,Spacetalk Ltd股票行情,Spacetalk Ltd股价,Spacetalk Ltd股市,Spacetalk Ltd股票价格,Spacetalk Ltd股票交易,Spacetalk Ltd股票购买,Spacetalk Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spacetalk Ltd(SPA.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spacetalk Ltd(SPA.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction